BioNTech SE (NASDAQ:BNTX) Short Interest Update

BioNTech SE (NASDAQ:BNTX) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 2,550,000 shares, an increase of 9.4% from the December 31st total of 2,330,000 shares. Based on an average trading volume of 806,600 shares, the days-to-cover ratio is currently 3.2 days.

Analysts Set New Price Targets

BNTX has been the topic of a number of recent analyst reports. BMO Capital Markets reiterated an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. HSBC lifted their price objective on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Canaccord Genuity Group raised their price target on shares of BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research note on Wednesday, November 27th. Wells Fargo & Company started coverage on BioNTech in a research note on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price objective on the stock. Finally, TD Cowen lowered their target price on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research note on Tuesday, November 5th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $142.72.

BioNTech Trading Down 3.2 %

BNTX traded down $3.95 during midday trading on Monday, reaching $119.82. 736,959 shares of the company’s stock traded hands, compared to its average volume of 749,984. The firm has a fifty day moving average of $117.34 and a two-hundred day moving average of $107.33. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The stock has a market capitalization of $28.73 billion, a price-to-earnings ratio of -57.06 and a beta of 0.17. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of ($1.26) by $2.07. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.73 EPS. On average, equities analysts anticipate that BioNTech will post -3.77 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Hedge funds and other institutional investors have recently made changes to their positions in the company. Planning Capital Management Corp increased its position in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares during the period. Blue Trust Inc. lifted its stake in BioNTech by 491.1% during the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after purchasing an additional 388 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after acquiring an additional 111 shares in the last quarter. AlphaCentric Advisors LLC acquired a new position in shares of BioNTech during the fourth quarter worth $168,000. Finally, Clear Harbor Asset Management LLC purchased a new position in shares of BioNTech during the third quarter worth approximately $210,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.